The hypothesis is that radiofrequency ablation combined or not with resection may allow a local control (the liver) in patients suffering from unresectable colorectal liver metastases. Patients may have benefit or not from a preoperative (neoadjuvant) chemotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
52
CHU d'Angers
Angers, France
Centre Saint Michel
Angoulême, France
CHU de Bordeaux
Bordeaux, France
Complete Hepatic Response Rate at 3 Months
Complete hepatic response (CHR) rate was defined as the absence of new hepatic lesions or contrast enhancement at the ablation and resection sites on CT performed at 2 and 3 months. CHR at 3 months was reported
Time frame: 3 months
Overall Survival
OS was defined as the time from the treatment initiation to death due to any cause. Participants without documented death were censored at the date of the last follow-up or last patient contact. The OS was calculated using the product-limit (Kaplan-Meier) method for censored data. 1-year and 2-year OS rate were reported.
Time frame: at 1 and 2 years
Event-free Survival
Event-free survival was measured from the date of intervention to the date of the first of the following events: initial failure, disease progression (hepatic or distant) or death (all causes). Patients who were alive and event-free were consored at the last documented date of follow-up. 1-year and 2-years EFS rates were reported.
Time frame: at 1 and 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest
Bordeaux, France
Hopital Béclère
Clamart, France
Hopital Sub-Urbain du Bouscat
Le Bouscat, France
Hopital de la Croix Rousse
Lyon, France
Hopital Saint Eloi
Montpellier, France
Centre Hospitalier
Niort, France
Centre de Radiothérapie et d'Oncologie Médicale
Pau, France
...and 2 more locations